Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
G-protein Coupled Receptors01:21

G-protein Coupled Receptors

G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Determinants of Repetitive Transcranial Magnetic Stimulation Efficacy in Tobacco Use Disorder: A Pre-Registered Study.

medRxiv : the preprint server for health sciences·2026
Same author

Ventrolateral prefrontal-amygdala repetitive transcranial magnetic stimulation (rTMS) modulation of impulsivity in borderline personality disorder: a proof-of-concept study.

Scientific reports·2026
Same author

Factors associated with treatment-emergent headache occurrence following RTMS to non-motor areas and the impact on treatment outcomes: a retrospective study.

Frontiers in psychiatry·2026
Same author

Effects of theta burst stimulation on neural connectivity and visual perception following attention modification of own-face viewing in body dysmorphic disorder.

medRxiv : the preprint server for health sciences·2026
Same author

A cell type-specific mechanism driving the rapid antidepressant effects of transcranial magnetic stimulation.

Cell·2026
Same author

The relationship between individual alpha-band activity and cognitive outcomes from repetitive Transcranial Magnetic Stimulation (rTMS) treatment for Major Depressive Disorder (MDD).

Journal of affective disorders·2026

Related Experiment Video

Updated: Jun 7, 2026

Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder
05:19

Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder

Published on: July 7, 2023

Biomarkers to predict antidepressant response.

Andrew F Leuchter1, Ian A Cook, Steven P Hamilton

  • 1Semel Institute for Neuroscience and Human Behavior at UCLA, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, USA. AFL@UCLA.EDU

Current Psychiatry Reports
|October 22, 2010
PubMed
Summary

Despite advances in understanding major depressive disorder (MDD), treatments often fail to achieve full recovery. Biomarkers show promise for guiding personalized antidepressant selection and improving patient outcomes.

More Related Videos

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
13:18

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression

Published on: April 10, 2026

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

Related Experiment Videos

Last Updated: Jun 7, 2026

Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder
05:19

Closed-Loop Neurostimulation for Biomarker-Driven, Personalized Treatment of Major Depressive Disorder

Published on: July 7, 2023

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
13:18

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression

Published on: April 10, 2026

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

Area of Science:

  • Neuroscience
  • Psychiatry
  • Genetics

Background:

  • Major depressive disorder (MDD) understanding has grown, but treatment outcomes remain suboptimal, with many patients not achieving full recovery.
  • Current clinical approaches rely heavily on trial-and-error, lacking a scientific basis for sequential treatment selection.
  • Standardized algorithms and measurement-based care are used, but a personalized medicine approach using biomarkers is lacking.

Purpose of the Study:

  • To explore the potential of incorporating physiological biomarkers into treatment algorithms for major depressive disorder (MDD).
  • To investigate how biomarker measurements can guide antidepressant selection and potentially accelerate patient recovery.
  • To assess the utility of various biomarker classes in predicting treatment response and outcome.

Main Methods:

  • Review of recent research on physiological biomarkers for predicting treatment response in MDD.
  • Analysis of potential biomarker classes including brain imaging, genomic, proteomic, and metabolomic measures.
  • Evaluation of biomarker utility at baseline or early in treatment for predicting outcome.

Main Results:

  • Several classes of physiological biomarkers show potential for predicting antidepressant treatment response.
  • Brain structural/functional findings, genomic, proteomic, and metabolomic measures are identified as potential predictors.
  • Biomarker measurements at baseline or early in treatment may predict treatment outcomes.

Conclusions:

  • Biomarkers hold significant potential for personalizing antidepressant treatment selection in MDD.
  • Validated biomarkers could form the foundation for new treatment paradigms, moving beyond trial-and-error.
  • Incorporating biomarkers could shorten recovery times and improve overall treatment effectiveness for MDD patients.